Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Holdings Trimmed by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P lowered its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 6.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 150,337 shares of the company’s stock after selling 9,933 shares during the period. Loomis Sayles & Co. L P’s holdings in Neurocrine Biosciences were worth $17,322,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of NBIX. Ashton Thomas Private Wealth LLC purchased a new stake in Neurocrine Biosciences in the 2nd quarter worth about $28,000. Innealta Capital LLC acquired a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at about $30,000. New Covenant Trust Company N.A. purchased a new stake in shares of Neurocrine Biosciences in the first quarter worth approximately $32,000. EdgeRock Capital LLC acquired a new stake in shares of Neurocrine Biosciences during the second quarter worth approximately $35,000. Finally, Blue Trust Inc. boosted its holdings in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $127.91 on Wednesday. The company’s fifty day moving average is $118.83 and its two-hundred day moving average is $131.74. The firm has a market capitalization of $12.95 billion, a price-to-earnings ratio of 34.29 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 52-week low of $110.52 and a 52-week high of $157.98.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on NBIX shares. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Royal Bank of Canada dropped their price target on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research note on Friday, October 4th. BMO Capital Markets reduced their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research report on Friday, November 1st. Finally, Raymond James reiterated an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Five investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.